Abstract:TNF antagonists may offer therapeutic potential in solid tumors, but patients who have high serum levels of TNF-a fail to respond to infliximab, suggesting consumption of the circulating antibody and loss of transmembrane TNF-a (tmTNF-a) on tumors by ectodomain shedding. Addressing this possibility, we developed a monoclonal antibody (mAb) that binds both full-length tmTNF-a and its N-terminal truncated fragment on the membrane after tmTNF-a processing but does not cross-react with soluble TNF-a. We documented high levels of tmTNF-a expression in primary breast cancers, lower levels in atypical hyperplasia or hyperplasia, but undetectable levels in normal breast tissue, consistent with the notion that tmTNF-a is a potential therapeutic target. Evaluations in vitro and in vivo further supported this assertion. tmTNF-a mAb triggered antibodydependent cell-mediated cytotoxicity against tmTNF-a–expressing cells but not to tmTNF-a–negative cells. In tumor-bearing mice, tmTNF-amAb delayed tumor growth, eliciting complete tumor regressions in some mice. Moreover, tmTNF-amAb inhibitedmetastasis and expression of CD44v6, a prometastaticmolecule. However, the antibody did not activate tmTNF-a–mediated reverse signaling, which facilitates tumor survival and resistance to apoptosis, but instead inhibited NF-kB activation and Bcl-2 expression by decreasing tmTNF-a–positive cells. Overall, our results established that tmTNF-a mAb exerts effective antitumor activities and offers a promising candidate to treat tmTNF-a–positive tumors, particularly in patients that are nonresponders to TNF antagonists. Cancer Res; 73(13); 4061–74. 2013 AACR. Introduction TNF-a exists in 2 bioactive forms: a 26-kD transmembrane form and a 17-kD soluble form that is released after proteolytic cleavage. Both forms of TNF-a display bioactivities via TNF receptors, TNFR I and TNFRII. TNF-a is a 2-edged sword for tumors. On the one hand, there is evidence that it induces tumor necrosis and apoptosis as its name implies. On the other hand, TNF-a is also reported to promote tumor development. Although our and others' previous studies reveal that the ectopic expression of TNF-a at the site of malignancy induces strong and long-term tumor regression (1, 2), increasing evidence indicates that TNF-a functions in promotion and progression of tumors, rather than in protection against tumors, including proliferation, transformation, angiogenesis, invasion, and metastasis in many cancers (3). Knockout of TNF-a or TNFR1 creates mice resistant to chemical carcinogenesis of the skin or liver, respectively (4, 5). Conversely, pretreatment with TNF-a enhances lung metastases (6), and overexpression of TNF-a confers invasive properties on xenograft tumors (7). In the clinic, TNF-a production by tumors is related with a poor prognosis, loss of hormone responsiveness, and cachexia (8, 9). Most studies on TNF-a and tumors refer to the soluble TNF-a (sTNF-a), a typical proinflammatory cytokine; thus, sTNF-a is considered to bridge inflammation and cancer. Although sTNF-a originates from the extracellular sequence of transmembrane TNF-a (tmTNF-a), the bioactivities of both forms of TNF-a are not quite the same. Our previous study shows that tmTNF-a is able to kill some tumor cell lines that are resistant to sTNF-mediated cytotoxicity (10). In contrast, tmTNF-a expressed by tumor cells protects them from apoptosis by inducing constitutive activation of NF-kB via its reverse signaling, as the ectopic expression of the leader sequence of tmTNF-a [namely deletion of the sTNF-a sequence, retaining N-terminal truncated fragment (NTF) including the intracellular part of tmTNF-a] is sufficient to activate NF-kB and render tumor cells resistant to apoptosis induced by sTNF-a (11, 12). Conversely, interruption of the reverse signaling mediated by tmTNF-a increases the sensitivity of tumor cells to sTNF-a–induced cytotoxicity (12). These data suggest that tmTNF-a may influence the opposite actions of sTNF-a, antior protumor. Furthermore, it may be a good tumor surface target for immunotherapy. Authors' Affiliations: Department of Immunology, Tongji Medical College; Department of Hematology, Tongji Hospital, Huazhong University of Science and Technology; and Department of Clinical Laboratory, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China M. Yu and X. Zhou contributed equally to this work. Corresponding Author: Zhuoya Li, Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei 430030, China. Phone: 86-27-83692611; Fax: 86-27-83693500; E-mail: Zhuoyali@mails.tjmu.edu.cn doi: 10.1158/0008-5472.CAN-12-3946 2013 American Association for Cancer Research. Cancer Research www.aacrjournals.org 4061 on May 11, 2014. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst June 21, 2013; DOI: 10.1158/0008-5472.CAN-12-3946

Growth Suppresses Breast Cancer α Targeting Transmembrane TNF-Updated

Targeting Transmembrane Tnf-Alpha Suppresses Breast Cancer Growth

Transmembrane TNF-alpha Promotes Chemoresistance in Breast Cancer Cells

Supplementary Methods from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Tissue Factor Overexpression in Triple-Negative Breast Cancer Promotes Immune Evasion by Impeding T-cell Infiltration and Effector Function.

Anti-TNFR2 Monoclonal Antibody LBL-019 in Patients with Advanced Malignant Tumors: A Phase I, First-in-human, Open-Label, Multicenter, Dose Escalation Study.

Mechanism of Action Differences in the Antitumor Effects of Transmembrane and Secretory Tumor Necrosis Factor-Alpha in Vitro and in Vivo.

Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth

Transmembrane TNF-A Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

Suppression of Transmembrane Tumor Necrosis Factor Alpha Processing by a Specific Antibody Protects Against Colitis-Associated Cancer

Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity.

Abstract 6800: The tumor progression mechanism of increasing CXCL16-CXCR6 pathway within the tumor microenvironment in TNBC

Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity.

Comparison of Antitumor Effects from Transmembrane and Secreted TNF-α in Vivo

Abstract A050: MDSC-derived transmembrane TNF is a central regulator of stromal inflammation and T-cell dysfunction in pancreatic cancer

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Abstract 4950: Abnormality of Selective Autophagic Degradation of Tenascin-C Promotes Resistance to T Cell-Mediated Immune Attack in Triple Negative Breast Cancer

[Inducement Effect of Recombinant Human TNF-alpha on Apoptosis of Breast Cancer Cell Line ZR75-1 and Its Mechanism].

Tumor Necrosis Factor-Α Alters Protein Metabolism and Cell-Cycle Kinetics in Malignant Tumor

Transmembrane TNF-α Preferentially Expressed by Leukemia Stem Cells and Blasts is a Potent Target for Antibody Therapy

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers